Eli Lilly, spurred by AI analysis, starts pivotal study of arthritis med Olumiant in COVID-19

Olumiant drug

Eli Lilly has started a phase 3 trial of arthritis med Olumiant in COVID-19, hoping to show the JAK inhibitor could cut the rate of death or the need for ventilation in hospitalized patients.